Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery (AZATAAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01889498|
Recruitment Status : Unknown
Verified December 2014 by Dr Mark Field, Liverpool Heart and Chest Hospital NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : June 28, 2013
Last Update Posted : December 31, 2014
|First Submitted Date ICMJE||June 4, 2013|
|First Posted Date ICMJE||June 28, 2013|
|Last Update Posted Date||December 31, 2014|
|Study Start Date ICMJE||July 2014|
|Estimated Primary Completion Date||June 2016 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Intracranial pressure recorded immediately after line insertion, throughout surgery and post-operatively (only recordings post-operatively will be treated as an end-point) [ Time Frame: hourly from start of surgery upto 72 hrs after surgery ]
reduction in intracranial pressure
|Original Primary Outcome Measures ICMJE||Same as current|
|Current Secondary Outcome Measures ICMJE
||Frequency and volume of CSF drainage [ Time Frame: hourly during and after the operation up to 72 hours ]
Reduction in frequency and volume of CSF drainage
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures
|Original Other Pre-specified Outcome Measures||Same as current|
|Brief Title ICMJE||Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery|
|Official Title ICMJE||A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair|
The aorta is a large vessel that carries blood away from the heart. Sometimes it becomes dilated (swells) and this is known as 'aneurysm'. It may cause either dissection (splitting of the wall) or rupture (bursting).
Treatments could be through open surgery or by use of stents (tubular mesh) through the groin. There is a risk of causing paraplegia, which is the loss/weakness of leg function as well as incontinence (loss of bladder and/or bowel control).
To try and prevent this, a number of techniques are used such as removing/draining of cerebrospinal fluid (CSF) (the clear fluid surrounding the brain and spinal cord).
In these situations, the use of a drug called acetazolamide may be helpful. This reduces the production of CSF and therefore decreases the need for CSF draining. It may also have an effect in decreasing the risk of paraplegia.
Patients will be randomly (by chance) placed into one of two groups. One will get the drug as tablets and injection and the other will not receive any acetazolamide at all. Blood tests will be done in both groups. We expect to have 100 patients in the study, with patient involvement for a total of 10 days (maximum).
Aortic aneurysms are classified according to the extent and position of the aorta involved: thoracic aneurysms (TA), include the ascending or descending aorta within the thoracic cavity, thoracic-abdominal aneurysms (TAA), involving the thoracic and abdominal aorta, and abdominal aortic aneurysms (AAA, involving the abdominal aorta). The outlook for patients with the most extensive aneurysms is very poor if treated medically with a 5 year survival of 20%1. Intervention has been shown to significantly improve survival to greater than 70% over 5 years 2. However, intervention comes with significant risk, with mortality between 3 and 40% and paraplegia between 5-20% dependent on the series1-2. Additional risks are of renal and pulmonary failure requiring prolonged intensive care unit stays. However, paraplegia remains of most concern to doctor and patient. Paraplegia is a consequence of the tenuous nature of the spinal cord blood supply originating from the aorta. Interruption of the blood supply during aortic repair is responsible for neurological dysfunction. Several adjuncts have been developed to reduce this risk including sequential clamping, left-heart bypass, evoked potentials, intercostal reattachment and cerebrospinal fluid (CSF) drainage- all of which are employed at the Liverpool Heart & Chest Hospital. Drainage of spinal fluid and reducing intracranial CSF pressure favours blood perfusion of the spine. In order to perform CSF drainage a spinal drain is inserted in patients preoperatively. This process is tightly regulated through the existing "Spinal Drainage Protocol" produced by the Trust. Issues arise in the following scenarios:
A hypothesis has been developed by the team that a drug called acetazolamide may be of use when these scenarios are encountered. Acetazolamide (carbonic anhydrase inhibitor) is a conventional diuretic but is also a drug used by travellers to counteract mountain sickness and one of its effects is to reduce CSF production. A low-dose (250mg orally) of the drug has been shown to be effective as a prophylaxis method in acute mountain sickness 3. Its oral form has also been utilised to reduce shunt CSF volume in children4. Additionally, Acetazolamide has been suggested as a 'first-line treatment' in Idiopathic intracranial hypertension 9, 10. To date, we have used this drug intravenously in 7 thoracic-abdominal patients, off licence, and had encouraging results (SEE APPENDIX 1) with a reduction of intracranial pressure (ICP) in some but not all patients. At the moment however, this drug is only licenced (approved by the Medicines and Healthcare products Regulatory Agency (MHRA)) for use in glaucoma, epileptic patients and patients with abnormal fluid retention. We hypothesize that the use of acetazolamide post operatively, in the 5 scenarios just described, results in the reduction of CSF production and hence ICP. Following from this we believe there was a reduced need for vasopressors and improved spinal cord blood perfusion. Undoubtedly in some patients this drug has a dramatic effect on CSF production, ICP and the need for drainage and vasopressors, all potential beneficial consequences. We do not know however whether the drug works in all patients and whether there are consequences from the other effects of this drug such as acidosis, hypercapnia or diuresis. In addition, we do not know whether the drug is best given preoperatively, as a prophylactic measure, or whether the preoperative treatment will improve the response to the intravenous postoperative dose. In addition, we do not know whether these measures which intuitively should lower the risk of paraplegia, actually translate into a lowering of this complication.
General hypothesis: Acetazolamide may safely be used as a preoperative prophylactic measure (orally), as well as postoperatively (intravenous) as a treatment measure when the spinal drain protocol is exceeded, to modify CSF production and reduce the risk of neurological impairment as measured biochemically, spectroscopically, electrically and clinically.
This study cannot be powered to test for a statistical effect on clinically evident paraplegia as its frequency in our institution is 5% thus at our current activity of 30 cases per year of TAA and ..??… cases of thoracic stents., the study would need to run over 5 years. The numbers are sufficient to demonstrate a significant change in the relatively common end-points noted below. This study therefore serves to prove the utility of acetazolamide in modifying factors we consider influential in the development of paraplegia. Should this study prove positive we aim to roll out to an international multicentre study to test for clinical effectiveness in reducing paraplegia.
Acetazolamide reduces the following clinically relevant end-points:
Research Objective: The randomised trial aims to investigate the inhibitory properties of the drug to decrease CSF production and reduce ICP, which would in effect decline paraplegia risk induced by elevated ICP.
Study design: A single-centre, randomized, unblinded, controlled trial comparing acetazolamide versus usual practice
Sample size: n=100 (50 patients per group)
Power calculation was estimated as follows:
We chose to recruit a total of 100 patients in the sample size due to the limitations of availability sufficient numbers of patients undergoing this type of surgery in a single centre.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 4|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Condition ICMJE||Thoracic Aneurysm|
|Intervention ICMJE||Drug: Acetazolamide
Acetazolamide twice a day, at 12 hour intervals:
Other Name: diamox
|Study Arms ICMJE||
|Publications *||Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, Norton HJ, Glaeser DH. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg. 1986 Mar;3(3):389-404.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Unknown status|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||June 2016|
|Estimated Primary Completion Date||June 2016 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages ICMJE||18 Years and older (Adult, Older Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United Kingdom|
|Removed Location Countries|
|NCT Number ICMJE||NCT01889498|
|Other Study ID Numbers ICMJE||954
2013-001447-31 ( EudraCT Number )
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement ICMJE||Not Provided|
|Responsible Party||Dr Mark Field, Liverpool Heart and Chest Hospital NHS Foundation Trust|
|Study Sponsor ICMJE||Liverpool Heart and Chest Hospital NHS Foundation Trust|
|Collaborators ICMJE||Not Provided|
|PRS Account||Liverpool Heart and Chest Hospital NHS Foundation Trust|
|Verification Date||December 2014|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP